search all
browse all
Previous Next

NIAC Letter to CMO re. Clarification of evidence relating to CIN1 HPV vaccination

Object Type: Asset
In Folder: Documents from 2023

Other Documents

sdb:SO|2fbe1ddb-7dd2-4a5c-a676-00b4f52cc618
11
NIAC Letter to CMO re. Clarification of evidence relating to CIN1 HPV vaccination

IO_fa6065ea-979d-4faa-94a3-76461c3d5e4b

NIAC Letter to CMO re. Comirnaty Omicron XBB.1.5 COVID-19 vaccine

IO_d726e12d-c50f-4586-9ac4-8bd783357902

NIAC Letter to CMO re. Nuvaxovid adapted XBB.1.5 vaccine

IO_8235cef9-b16d-43bc-b7fd-71cb44498599

NIAC Letter to CMO re. Review of Autumn 2023 COVID-19 booster recommendations

IO_0148c60b-78ee-43d5-bc0f-675038feb40d

NIAC letter to CMO re. Timing of administration of COVID-19 booster vaccines in pregnancy

IO_243fb665-1b86-486d-82f9-8933e53cadc6

NIAC Updated recommendations for Primary Series COVID-19 Vaccination

IO_6937860a-7750-4860-9db4-4c24c25afd95

Recommendations for COVID-19 vaccination of children aged 6 months to 4 years

IO_f1476689-964a-46b3-9e1e-f72673240ebd

Recommendations for passive immunisation and vaccination against respiratory syncytial in infants, children and older adults

IO_9275434a-99ff-44e5-b19c-04771ba2b1c0

Recommendations re. 2023 COVID-19 Vaccination Strategy_Version_1.1

IO_64ff2bd6-bbc4-42bc-9c03-6afbbcd4e918

Recommendations re. Polio re-emergence

IO_748d4131-3819-4f37-abf9-5be399636072

Recommendations regarding immunisation of children aged 2 months to 5 years

IO_1841509f-a674-498b-9bc9-0fe15df3d091

Powered by Preservica
© Copyright 2024
©2024 Preservica